Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

Dagogo-Jack I, Piotrowska Z, Cobb R, Banwait M, Lennerz JK, Hata AN, Digumarthy SR, Sequist LV.

J Thorac Oncol. 2019 Oct;14(10):e226-e228. doi: 10.1016/j.jtho.2019.05.046. No abstract available.

PMID:
31558234
2.

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.

Digumarthy SR, Mendoza DP, Padole A, Chen T, Peterson PG, Piotrowska Z, Sequist LV.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1360. doi: 10.3390/cancers11091360.

3.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.

Raoof S, Mulford IJ, Frisco-Cabanos H, Nangia V, Timonina D, Labrot E, Hafeez N, Bilton SJ, Drier Y, Ji F, Greenberg M, Williams A, Kattermann K, Damon L, Sovath S, Rakiec DP, Korn JM, Ruddy DA, Benes CH, Hammerman PS, Piotrowska Z, Sequist LV, Niederst MJ, Barretina J, Engelman JA, Hata AN.

Oncogene. 2019 Sep;38(37):6399-6413. doi: 10.1038/s41388-019-0887-2. Epub 2019 Jul 19.

PMID:
31324888
4.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.

Marcar L, Bardhan K, Gheorghiu L, Dinkelborg P, Pfäffle H, Liu Q, Wang M, Piotrowska Z, Sequist LV, Borgmann K, Settleman JE, Engelman JA, Hata AN, Willers H.

Cell Rep. 2019 Jun 18;27(12):3422-3432.e4. doi: 10.1016/j.celrep.2019.05.058.

5.

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung Cancer.

Fintelmann FJ, Troschel FM, Kuklinski MW, McDermott S, Petranovic M, Digumarthy SR, Sharma A, Troschel AS, Price MC, Hariri LP, Gilman MD, Shepard JO, Sequist LV, Piotrowska Z.

Oncologist. 2019 May 31. pii: theoncologist.2019-0158. doi: 10.1634/theoncologist.2019-0158. [Epub ahead of print]

PMID:
31152082
6.

Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.

Grassberger C, McClatchy D 3rd, Geng C, Kamran SC, Fintelmann F, Maruvka YE, Piotrowska Z, Willers H, Sequist LV, Hata AN, Paganetti H.

Cancer Res. 2019 Jul 15;79(14):3776-3788. doi: 10.1158/0008-5472.CAN-18-3652. Epub 2019 May 21.

PMID:
31113818
7.

Differences in leptin biosynthesis in the stomach and in serum leptin level between men and women.

Kasacka I, Piotrowska Ż, Niezgoda M, Łebkowski W.

J Gastroenterol Hepatol. 2019 Apr 24. doi: 10.1111/jgh.14688. [Epub ahead of print]

PMID:
31017682
8.

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.

Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE.

Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13.

PMID:
30790338
9.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

PMID:
30550363
10.

Sex differences in distribution of cannabinoid receptors (CB1 and CB2), S100A6 and CacyBP/SIP in human ageing hearts.

Piotrowska Ż, Niezgoda M, Łebkowski W, Filipek A, Domian N, Kasacka I.

Biol Sex Differ. 2018 Nov 27;9(1):50. doi: 10.1186/s13293-018-0209-3.

11.

Comparative evaluation of CacyBP/SIP protein, β-catenin, and immunoproteasome subunit LMP7 in the heart of rats with hypertension of different etiology.

Kasacka I, Piotrowska Ż, Weresa J, Filipek A.

Exp Biol Med (Maywood). 2018 Nov 24:1535370218815435. doi: 10.1177/1535370218815435. [Epub ahead of print]

PMID:
30472885
12.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

13.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
14.

Comparative evaluation of cannabinoid receptors, apelin and S100A6 protein in the heart of women of different age groups.

Kasacka I, Piotrowska Ż, Filipek A, Lebkowski W.

BMC Cardiovasc Disord. 2018 Oct 4;18(1):190. doi: 10.1186/s12872-018-0923-0.

15.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
16.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
17.

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

Piotrowska Z, Fintelmann FJ, Sequist LV, Jahagirdar B.

J Thorac Oncol. 2018 Oct;13(10):e204-e206. doi: 10.1016/j.jtho.2018.05.017. No abstract available.

18.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB.

Clin Cancer Res. 2018 Dec 15;24(24):6548-6555. doi: 10.1158/1078-0432.CCR-18-1541. Epub 2018 Aug 28.

PMID:
30154228
19.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00263. Epub 2018 Jul 16.

20.

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

Piotrowska Z, Gainor JF.

J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4. No abstract available.

PMID:
29864378
21.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Khandekar MJ, Piotrowska Z, Willers H, Sequist LV.

Oncologist. 2018 Sep;23(9):1054-1062. doi: 10.1634/theoncologist.2017-0557. Epub 2018 Apr 27. Review.

22.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

23.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH.

Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

24.

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.

Song KA, Niederst MJ, Lochmann TL, Hata AN, Kitai H, Ham J, Floros KV, Hicks MA, Hu H, Mulvey HE, Drier Y, Heisey DAR, Hughes MT, Patel NU, Lockerman EL, Garcia A, Gillepsie S, Archibald HL, Gomez-Caraballo M, Nulton TJ, Windle BE, Piotrowska Z, Sahingur SE, Taylor SM, Dozmorov M, Sequist LV, Bernstein B, Ebi H, Engelman JA, Faber AC.

Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19.

25.

The Role of Liquid Biopsies in Lung Cancer Screening.

Dagogo-Jack I, Sequist LV, Piotrowska Z.

Semin Roentgenol. 2017 Jul;52(3):185-187. doi: 10.1053/j.ro.2017.06.001. Epub 2017 Jun 3. Review. No abstract available.

PMID:
28734402
26.

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

Farago AF, Piotrowska Z, Sequist LV.

J Clin Oncol. 2017 Sep 10;35(26):2987-2988. doi: 10.1200/JCO.2017.73.5696. Epub 2017 Jul 10. No abstract available.

PMID:
28692381
27.

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

Piotrowska Z, Sequist LV.

J Thorac Oncol. 2017 Mar;12(3):419-421. doi: 10.1016/j.jtho.2017.01.018. No abstract available.

28.

Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.

Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I.

J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1073-1078.

PMID:
28078856
29.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV.

JCO Precis Oncol. 2017;1. doi: 10.1200/PO.17.00123. Epub 2017 Nov 7. No abstract available.

30.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Nov 14;7:13513. doi: 10.1038/ncomms13513. No abstract available.

31.

Renovascular hypertensive decrease immunoreactivity of cells containing chromogranin A and pancreastatin in the pancreas of rats.

Piotrowska Ż, Janiuk I, Lewandowska A, Kasacka I.

Histol Histopathol. 2017 Jan;32(1):69-75. doi: 10.14670/HH-11-771. Epub 2016 Apr 25.

PMID:
27109936
32.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

Bauman JR, Piotrowska Z, Muzikansky A, Gallagher E, Scribner E, Temel B, Sequist LV, Heist RS, Temel JS.

J Palliat Med. 2016 Dec;19(12):1316-1319. Epub 2016 Sep 14.

PMID:
27626514
33.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M.

Nat Commun. 2016 Jun 10;7:11815. doi: 10.1038/ncomms11815. Erratum in: Nat Commun. 2016 Nov 14;7:13513.

34.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, Howe E, Farago AF, Sullivan RJ, Stone JR, Digumarthy S, Moran T, Hata AN, Yagi Y, Yeap BY, Engelman JA, Mino-Kenudson M.

Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.

35.

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

Piotrowska Z, Sequist LV.

JAMA Oncol. 2016 Jul 1;2(7):948-54. doi: 10.1001/jamaoncol.2016.0333. Review.

PMID:
27196961
36.

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

Piotrowska Z, Drapkin B, Engelman JA, Nagy RJ, Lanman RB, Sequist LV.

J Thorac Oncol. 2016 Aug;11(8):e95-e97. doi: 10.1016/j.jtho.2016.03.020. Epub 2016 Apr 12. No abstract available.

37.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.

Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, Maruvka YE, Ji F, Bhang HE, Krishnamurthy Radhakrishna V, Siravegna G, Hu H, Raoof S, Lockerman E, Kalsy A, Lee D, Keating CL, Ruddy DA, Damon LJ, Crystal AS, Costa C, Piotrowska Z, Bardelli A, Iafrate AJ, Sadreyev RI, Stegmeier F, Getz G, Sequist LV, Faber AC, Engelman JA.

Nat Med. 2016 Mar;22(3):262-9. doi: 10.1038/nm.4040. Epub 2016 Feb 1.

38.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

Sequist LV, Piotrowska Z, Niederst MJ, Heist RS, Digumarthy S, Shaw AT, Engelman JA.

JAMA Oncol. 2016 Apr;2(4):541-3. doi: 10.1001/jamaoncol.2015.5009. No abstract available.

PMID:
26720284
39.

Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive rats.

Kasacka I, Piotrowska Ż, Filipek A, Majewski M.

Exp Biol Med (Maywood). 2016 Feb;241(4):375-81. doi: 10.1177/1535370215611972. Epub 2015 Oct 28.

40.

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Piotrowska Z, Sequist LV.

Oncologist. 2015 Nov;20(11):1230-2. doi: 10.1634/theoncologist.2015-0370. Epub 2015 Oct 23. No abstract available.

41.

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.

Piotrowska Z, Sequist LV.

Cancer J. 2015 Sep-Oct;21(5):371-7. doi: 10.1097/PPO.0000000000000147. Review.

PMID:
26389761
42.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

Al-Halabi H, Sayegh K, Digamurthy SR, Niemierko A, Piotrowska Z, Willers H, Sequist LV.

J Thorac Oncol. 2015 Nov;10(11):1601-7. doi: 10.1097/JTO.0000000000000648.

43.

Influence of renovascular hypertension on the distribution of vasoactive intestinal peptide in the stomach and heart of rats.

Kasacka I, Piotrowska Ż, Janiuk I.

Exp Biol Med (Maywood). 2015 Nov;240(11):1402-7. doi: 10.1177/1535370215587533. Epub 2015 May 19. Erratum in: Exp Biol Med (Maywood). 2016 May;241(9):1014.

44.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, Sequist LV, Engelman JA.

Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.

45.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, Parks MK, DiCecca RH, Dias-Santagata D, Iafrate AJ, Shaw AT, Allen AR, Engelman JA, Sequist LV.

Cancer Discov. 2015 Jul;5(7):713-22. doi: 10.1158/2159-8290.CD-15-0399. Epub 2015 May 1.

46.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

47.

Alterations of rat stomach endocrine cells under renovascular hypertension.

Kasacka I, Piotrowska Z, Lewandowska A.

Adv Med Sci. 2014 Sep;59(2):190-5. doi: 10.1016/j.advms.2014.01.004. Epub 2014 Jun 9.

PMID:
25323756
48.

Evaluation of CART-, glucagon-, and insulin-immunoreactive cells in the pancreas of an experimental rat model of unilateral renal artery stenosis.

Kasacka I, Janiuk I, Piotrowska Z.

Histol Histopathol. 2015 Apr;30(4):445-52. doi: 10.14670/HH-30.445. Epub 2014 Sep 17.

PMID:
25229552
49.

Quantitative and qualitative evaluation of CART-containing cells in adrenal glands of male rats with hypertension.

Kasacka I, Piotrowska Ż, Knaś M, Lewandowska A.

Biotech Histochem. 2014 Oct;89(7):497-504. doi: 10.3109/10520295.2014.902503. Epub 2014 Aug 25.

PMID:
25151991
50.

Dynamics of cocaine- and amphetamine-regulated transcript containing cell changes in the adrenal glands of two kidney, one clip rats.

Kasacka I, Piotrowska Z, Janiuk I, Zbucki R.

Exp Biol Med (Maywood). 2014 Oct;239(10):1292-9. doi: 10.1177/1535370214538593. Epub 2014 Jun 17.

PMID:
24939825

Supplemental Content

Loading ...
Support Center